J&J Trying To Back Out Of 77 Risperdal Deals, Plaintiffs Say

Law360, Philadelphia (November 12, 2013, 6:46 PM EST) -- A group of nearly 80 plaintiffs pursuing lawsuits against a Johnson & Johnson subsidiary in Pennsylvania state court over injuries they allegedly suffered from the antipsychotic drug Risperdal said last week that the company was attempting to renege on settlement deals agreed to in January.

The plaintiffs, who allege they were improperly prescribed the drug off-label after a major marketing push by J&J unit Janssen Pharmaceuticals Inc., said on Nov.5 that the company has refused to finalize settlements it agreed to in January in 77 cases...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.